Patents by Inventor Andriy M. Kornilov

Andriy M. Kornilov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites
    Patent number: 8680327
    Abstract: The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: March 25, 2014
    Assignee: Cayman Chemical Company, Incorporated
    Inventors: Gregory W. Endres, Andriy M. Kornilov, Adam Uzieblo
  • METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES
    Publication number: 20120041229
    Abstract: The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites.
    Type: Application
    Filed: June 14, 2011
    Publication date: February 16, 2012
    Applicant: Cayman Chemical Company, Incorporated
    Inventors: Gregory W. Endres, Andriy M. Kornilov, Adam Uzieblo
  • TETRANOR-PGDM/PGJM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME
    Publication number: 20120021437
    Abstract: Tetranor-PGDM/tetranor-PGJM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses in assay kits for detecting and quantifying tetranor-PGDM and tetranor-PGJM in biological fluids for determining biosynthesis of PGD2 in a subject or patient.
    Type: Application
    Filed: June 14, 2011
    Publication date: January 26, 2012
    Applicant: Cayman Chemical Company, Incorporated
    Inventors: Jeffrey K. Johnson, Kirk M. Maxey, Daniel J. Tew, Andriy M. Kornilov
  • TETRANOR-PGEM/PGAM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME
    Publication number: 20110311990
    Abstract: Tetranor-PGEM/tetranor-PGAM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses for detecting and quantifying tetranor-PGEM in biological fluids for determining biosynthesis of PGE2 in a subject or patient.
    Type: Application
    Filed: June 14, 2011
    Publication date: December 22, 2011
    Applicant: Cayman Chemical Company, Incorporated
    Inventors: Jeffrey K. Johnson, Kirk M. Maxey, Daniel J. Tew, Andriy M. Kornilov
  • Prostaglandin E1 and E2 analogs for the treatment of various medical conditions
    Patent number: 8063240
    Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: November 22, 2011
    Assignee: Cayman Chemical Company, Incorporated
    Inventors: Nancy S. Barta, Stephen D. Barrett, Gregory W. Endres, Andriy M. Kornilov, Kirk M. Maxey, Adam Uzieblo